695172-02-2Relevant articles and documents
The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics
Van Soom, Jeroen,Cuzzucoli Crucitti, Giuliana,Gladysz, Rafaela,Van Der Veken, Pieter,Di Santo, Roberto,Stuyver, Ingmar,Buck, Victoria,Lambeir, Anne-Marie,Magdolen, Viktor,Joossens, Jurgen,Augustyns, Koen
, p. 1954 - 1958 (2015/11/17)
KLK4 is a serine protease from the kallikrein family that is involved in cancer progression. The diphenyl phosphonate warhead is intended to bind irreversibly with serine proteases, but unexpectedly, very potent KLK4 diphenyl phosphonate inhibitors were d
A p-[18F]fluoroethoxyphenyl bicyclic nucleoside analogue as a potential positron emission tomography imaging agent for varicella-zoster virus thymidine kinase gene expression
Chitneni, Satish K.,Deroose, Christophe M.,Balzarini, Jan,Gijsbers, Rik,Celen, Sofie,Debyser, Zeger,Mortelmans, Luc,Verbruggen, Alfons M.,Bormans, Guy M.
, p. 6627 - 6637 (2008/09/17)
We recently reported a new positron emission tomography (PET) reporter gene, namely, varicella-zoster virus thymidine kinase (VZV-tk) in combination, with carbon-11 or fluorine-18 labeled m-alkoxyphenyl bicyclic nucleoside analogues (BCNAs) as PET reporte
NOVEL UROKINASE INHIBITORS
-
Page/Page column 81-83; 85-86, (2010/11/27)
The present invention relates to novel compounds with inhibitory activity towards urokinase plasminogen activator (uPA); to methods for preparation of said uPA inhibitor compounds; to pharmaceutical compositions comprising said uPA inhibitor compounds; to